Barclays is “increasingly cautious” on WeightWatchers (WW) following a recent study from Novo Nordisk (NVO) that yielded negative datapoints around the investigated differences between the company’s own manufactured semaglutide and liraglutide against compounders. While the firm expects compounding will remain a presence until supply constraints ease it continues to view WW’s move toward compounded GLP-1s as “having more risk than reward” and with WW’s stock up nearly 150% since the company announced its compounded GLP-1 offering, Barclays sees incremental downside risk to shares. The firm reiterates an Underweight rating and 75c price target on WW shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WW:
- 3 Penny Stocks to Watch Now, 10/10/24
- Unusually active option classes on open October 9th
- WW launching compounded semaglutide, but estimates too high, says Craig-Hallum
- Barclays does not view compounding as durable business model for WeightWatchers
- PepsiCo reports mixed Q3, Roblox slips after short report: Morning Buzz